Running title: Optoacoustic imaging of tumor cell death Abstract Purpose: The development of new treatments and their deployment in the clinic may be assisted by imaging methods that allow an early assessment of treatment response in individual patients. The C2A domain of Synaptotagmin-I (C2Am), which binds to the phosphatidylserine (PS) exposed by apoptotic and necrotic cells, has been developed as an imaging probe for detecting cell death. Multispectral optoacoustic tomography (MSOT) is a real-time and clinically applicable imaging modality that was used here with a near infrared (NIR) fluorophore-labeled C2Am to image tumor cell death in mice treated with a TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) agonist and with 5-fluorouracil (5-FU). Experimental design: C2Am was labeled with a near infrared (NIR) fluorophore and injected intravenously into mice bearing human colorectal TRAIL-sensitive Colo205 and TRAIL-resistant HT-29 xenografts that had been treated with a potent agonist of TRAILR2 and in Colo205 tumors treated with 5-FU. Results: Three dimensional MSOT images of probe distribution showed development of tumor contrast within 3 h of probe administration and a signal-tobackground ratio in regions containing dead cells of >10 after 24 h. A site-directed mutant of C2Am that is inactive in PS binding showed negligible binding. Tumor retention of the active probe was strongly correlated (R 2 =0.97, P value<0.01) with a marker of apoptotic cell death measured in histological sections obtained post mortem.
Statement of translational relevance:
Tumors of the same type can show markedly different responses to the same treatment. The development of new treatments and their deployment in the clinic would benefit, therefore, from the introduction of imaging methods that allow an early assessment of treatment response in individual patients, allowing rapid selection of the most effective treatment for a specific patient. Multispectral optoacoustic tomography (MSOT) is a clinically applicable, real-time imaging modality that can generate relatively high-resolution cross-sectional images at depth. We show here that when used with a near infra-red (NIR) fluorophore-labelled probe that binds to apoptotic and necrotic cells MSOT can be used to image tumor cell death within an entire tumor volume. The technique can be used to characterize the heterogeneous response of a tumor to treatment and to determine the most effective therapy at an early stage following the start of treatment.
Introduction
DNA sequencing of tumor biopsies or of circulating tumor DNA (ctDNA), and detection of early treatment response through increases in the levels of ctDNA, are expected to play an increasingly important role in selecting treatment for individual patients (1, 2) . However, tumor heterogeneity remains an obstacle for both approaches. Biopsies may not detect all clones present within a tumor and the presence of residual treatment-resistant clones may not be reflected in the levels of ctDNA released following treatment. Imaging methods that can detect treatment response throughout the entire tumor volume are likely, therefore, to play an important role in treatment selection (3) .
Tumor cell death represents a generic downstream marker of treatment response and consequently there has been considerable interest in developing imaging methods and agents to detect tumor cell death in vivo (4) . We have developed a targeted imaging agent based on the C2A domain of Synaptotagmin-I, which binds with nanomolar affinity to the phosphatidylserine (PS) exposed on the plasma membrane of dying cells (5) . The protein was used initially as a glutathione-Stransferase (GST) fusion protein, where imaging labels were attached to lysine residues, and used to detect tumor cell death using magnetic resonance and radionuclide imaging (6) (7) (8) (9) . Subsequently, we developed a much smaller derivative of C2A (16 kDa) based on the isolated C2A domain (C2Am), in which we introduced a unique cysteine residue distant from the PS binding site. This allowed site-specific attachment of imaging labels, without affecting binding affinity, and the production of a chemically homogeneous preparation of the agent. The smaller size allows for relatively rapid renal clearance, the production of a homogeneous agent rules out the possibility of labeled material that does not bind PS, or shows only weak binding, and the removal of the GST tag, by lowering potential immunogenicity, increases clinical translatability. C2Am, when labeled with a fluorophore, showed better specificity for binding to dead cells than a similarly labeled Annexin V derivative (5) .
Fluorescently labeled Annexin V is widely used to detect cell death in vitro and, in radionuclide-labeled form, has also translated to the clinic. However, clinical use of this agent was limited by poor specificity and relatively high levels of background binding (10) .
The relatively high sensitivity, minimal tissue absorption and low cost of near infrared (NIR) fluorescence imaging have made this a widely used technique for noninvasive imaging in small animals (11) and increasingly in the clinic (12) . However, image depth and resolution are limited by scattering, with depths of 1-2 cm and resolutions of 1-2 mm (13) . Optoacoustic imaging can give three-dimensional (3D) tomographic images and can generate relatively high-resolution images at depths of a few centimeters. In this technique NIR radiation is administered in the form of nanosecond laser pulses. Absorption by chromophores in endogenous materials, such as oxy-and deoxyhemoglobin and melanin, or in contrast agents introduced exogenously, results in thermoelastic expansion and the production of a pressure wave that can be detected non-invasively using ultrasound transducers. Since pressure waves are relatively low frequency they are scattered much less than light or NIR radiation and so can be used to generate much higher resolution images.
Detectors operating around 5 MHz enable penetration depths of several centimeters with resolutions between 100-400 μm, while detectors operating in the 10-100 MHz frequency range penetrate 1-10 mm with resolutions in the tens of micrometres (14) .
In multispectral optoacoustic tomography (MSOT) measurements are made at several NIR wavelengths in less than a second, which enables real-time imaging of individual chromophores within entire tumor volumes. With the introduction of a hand held device, bed-fitted devices and the development of real-time threedimensional optoacoustic tomography (14, 15) , clinical applications of MSOT have started to emerge, including screening of dense breasts for the presence of tumors (16, 17) , monitoring the metastatic status of sentinel lymph nodes in melanoma patients (18) and assessment of inflammatory disease (19) .
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) is a death receptor upregulated in a wide range of human tumors (20) (21) (22) , which upon ligation triggers apoptosis through activation of a caspase cascade.
MEDI3039 is a multivalent TRAILR2 agonist that can induce cell death in tumor cells at picomolar concentrations (23, 24) .
We describe here in vivo imaging measurements of early tumor responses to MEDI3039, and also 5-FU, using NIR fluorophore-labeled C2Am, using both optical imaging and MSOT. Non-specific probe binding was assessed using a site-directed mutant that is inactive in PS binding (iC2Am) (25) . The MSOT signal from C2Am was increased significantly in MEDI3039 and 5-FU-treated Colo205 tumors as early as 3 h post probe injection, whereas there was negligible retention of iC2Am in MEDI3039-treated tumors. Subsequent histological analyses showed that the C2Am signal observed in vivo was strongly correlated with immunostaining of dead cells in tumor sections. 
Materials and methods

Conjugates of C2Am and iC2Am.
Conjugates of C2Am and iC2Am with VivoTag ® -S 750-MAL (excitation wavelength: 750±5nm; emission wavelength: 775±5nm, PerkinElmer, Waltham, MA) and iC2Am with IRDye ® 680RD (excitation wavelength: 672nm; emission wavelength: 694nm, LI-COR Biosciences, Lincoln, NE) were prepared as described previously (5) . This conjugation protocol has been shown previously to produce conjugates of C2Am and iC2Am that were fully modified, yielding a single molecular species on electrospray ionization mass spectrometry (5, 25) . The optical absorption spectrum of 1 μM C2Am-750 in phosphate-buffered saline (PBS) was measured using a PHERAStar FS spectrometer (BMG LABTECH, Bucks, UK). water bath maintained at a temperature of 36°C. MSOT measurements were performed before and at 3, 5, 7 and 24 h after probe injection, according to a protocol described previously (28) . Cross-sectional multispectral image datasets were acquired at different wavelengths in the NIR window (660, 665, 670, 680, 690, 700, 710, 720, 730, 740, 750, 755, 760, 770, 780, 800, 825, 850 and 900 nm) through the entire tumor region in 0.5 mm steps in the z-direction and at a single position where the kidneys were located. Scans at each illumination wavelength took 100 ms to acquire, and 10 averages were used to produce a final image, amounting to 20 s acquisition time per slice. Images were reconstructed using a model-based reconstruction algorithm, after which linear spectral unmixing was applied to each set of multi-wavelength images to resolve the biodistribution of the different tissue chromophores i.e. (i)C2Am-750, oxygenated and deoxygenated hemoglobin. Data were processed and quantified using the ViewMSOT software (iThera Medical). Histopathology. Tumors were fixed in 4% formaldehyde and embedded in paraffin.
Five µm sections were cut and imaged using the 700 nm and 800 nm channels of an Odyssey Infrared Imaging scanner (LI-COR). Images were generated at a resolution of 21 μm using two lasers, one emitting at 685 nm and the other at 785 nm. 
Results
HT-29 cells were largely resistant to MEDI3039, showing minimal loss of viability up
to 10 pM drug concentration and only ~25% loss at much higher drug concentrations, whereas Colo205 cells showed ~50% loss of viability at low drug concentrations (EC50 1.3 pM) and complete loss of viability at higher drug concentrations ( Figure   1A ). This loss of viability, measured by Trypan blue dye exclusion, was mirrored in Colo-Dual cells by loss of bioluminescence ( Figure 1B&C ). Colo-Dual cells were transduced with a lentiviral vector to express firefly luciferase and the red fluorescent protein, mStrawberry. The bioluminescence signal from these cells is indicative of intracellular ATP concentration. Binding of C2Am labeled with a fluorescent dye excited at 750 nm (C2Am-750) and a site-directed mutant inactive in PS binding labeled with a fluorescent dye excited at 672nm (iC2Am-680) to MEDI3039-treated cells was characterized using confocal microscopy ( Figure 2A ) and flow cytometry ( Figure 2B ). The specificity of C2Am-750 for PS binding was confirmed by a blocking study with unlabeled C2Am (Supplementary Figure 1) . Confocal microscopy measurements with Colo205-Dual cells treated with MEDI3039, showed that when compared to untreated cells there were relatively low levels of both NADH (intrinsic autofluorescence) and mStrawberry fluorescence, indicating cell death. These cells showed binding of C2Am-750 to the plasma membrane but negligible binding of iC2Am-680. There was negligible binding of C2Am-750 to untreated cells ( Figure   2A ). Flow cytometry of MEDI3039-treated TRAIL-sensitive Colo205 cells, but not TRAIL-resistant HT-29 cells, showed increased binding of C2Am-750, which was correlated with a decrease in NADH autofluorescence and an increase in binding of a cell necrosis marker, Sytox Green ( Figure 2B ). iC2Am-680 showed negligible binding to either cell line, regardless of drug treatment.
Next, we investigated the capability of C2Am-750 to detect tumor cell death in vivo, in Colo205 and HT-29 xenografts in BALB/c nu/nu mice. Three hours after probe injection, there was a significant increase in C2Am-750 retention in treated as compared to untreated Colo205 tumors, which was observed both in fluorescence measurements made in vivo (5.97-fold, P < 0.001) and on excised tumors ex vivo (4.1-fold, P value < 0.001) ( Figure 3 ). Compared to C2Am-750, the retention of iC2Am-680 was significantly lower in both treated (P <0.001) and untreated (P <0.001) tumors. These results were similar to those obtained previously with 5fluorouracil (5-FU)-treated Colo205 tumors (250 mg/kg of body weight; injected intraperitoneally), in which C2Am and iC2Am, both labeled with AlexaFluor™-750 C5-maleimide, were injected separately (25) . There was no significant difference in C2Am-750 retention in treated and untreated HT-29 xenografts, which was comparable to the retention observed in untreated Colo205 tumors ( Supplementary   Figure 2 ). iC2Am-680 retention was much lower in both groups. Fluorescence images of Colo205 tumor sections showed strong fluorescence signals from C2Am-750 (green) that co-localized with regions stained with TUNEL (a marker of necrotic cell death) and cleaved caspase 3 (CC3, a marker of apoptotic cell death). There was negligible signal from iC2Am-680 (blue), confirming the specificity of C2Am-750 for binding to dead and dying cells ( Figure 3B ). Measurements of bioluminescence from Colo-Dual tumors showed that at this single dose of MEDI3039 (0.4 mg/kg) there was a complete loss of signal within 24 h of drug treatment, which was maintained for up to 45 days after treatment ( Figure 4A ). The rapid loss of bioluminescence in treated tumors, presumably due to loss of ATP ( Figure 4B ), preceded decreases in tumor volume, which started one week after treatment.
Next, we used MSOT to image retention of C2Am-750 and iC2Am-750 in MEDI3039treated Colo205 tumors. The system used here had a spatial resolution of ~150 µm at a penetration depth of 3 cm. Spectral unmixing was used to generate images of C2Am-750, iC2Am-750 and intrinsic tissue chromophores (deoxygenated and oxygenated hemoglobin) throughout the entire tumor volume. Representative MSOT images show that there was some retention of C2Am-750 in untreated tumors ( Figure 5A ). However, signal from C2Am-750 was increased markedly at 7 h after drug treatment and 3 h after probe injection. Maximal signal from C2Am-750 appeared in the center of the treated tumors ( Figure 5B ), whereas there was negligible retention of iC2Am-750 ( Figure 5C ). Signal from kidney cortex confirmed that similar concentrations of C2Am-750 and iC2Am-750 had been injected in these animals. Axial, coronal and sagittal views showed that C2Am-750 was distributed throughout the entire tumor volume ( Figure 5D ). Images reconstructed in three dimensions are shown in Figure 5E (video representations of these images are in supplementary data). An MSOT absorption spectrum from a region of high signal intensity at the center of a MEDI3039-treated tumor obtained 3 h after injection of C2Am-750 was similar to the optical absorption spectrum of C2Am-750 measured in vitro ( Supplementary Figure 3) , demonstrating that the MSOT signal observed in vivo arose predominantly from C2Am-750.
Dynamic MSOT measurements with C2Am-750 and iC2Am-750 in MEDI3039treated Colo205 tumors and parallel fluorescence images acquired from the same animals are shown in Figure 6 . Both the MSOT ( Figure 6A ) and fluorescence images ( Figure 6B ) showed tumor retention of C2Am-750 for up to 24 h following probe injection, whereas there were only very low levels of iC2Am-750 in the tumor at 3 h and this had cleared by 24 h. At 24 h, the tumor signal-to-background ratio in animals injected with C2Am-750, in regions where there were high levels of C2Am-750 binding, increased from 1.3 ± 0.5 prior to probe injection to 15.0 ± 4.0 following probe injection (ratio ± S.E.M., n = 5), whereas this ratio did not change in animals injected with iC2Am-750 ( Figure 6C ). The average volume occupied by bound C2Am in drug-treated tumors at 24 h post probe injection was correlated with CC3 staining of tumor sections obtained post mortem, where the tumors were excised immediately following imaging (R 2 =0.97, P value<0.01) ( Figure 6D ). Similar fluorescence signal intensities for C2Am-750 and iC2Am-750 were observed in the kidneys of these animals, confirming again that similar concentrations of the two probes had been injected.
We have shown previously that fluorescently labeled C2Am can detect cell death in EL4 murine lymphoma cells treated with etoposide and MDA-MB-231 human breast cancer cells treated with doxorubicin (5) and that C2Am labeled with fluorescent and radionuclide labels can detect cell death in etoposide-treated EL4 tumors, cyclophosphamide-treated Eμ-myc tumors and Colo205 tumors treated with 5-FU (25) . Results of MSOT experiments with C2Am-750 in 5-FU-treated Colo-205 tumors are shown in Supplementary Figure 4 . There was a significant increase in the MSOT signal from C2Am-750 at 24 h after 5-FU treatment and 3 h after probe injection. A biodistribution study based on C2Am-750 fluorescence showed a significant increase in C2Am-750 retention in excised tumors compared to that in blood (4.05-fold, P < 0.001). Biodistribution data for fluorophore-labeled (i)C2Am-750 has been reported previously, where we showed that the biodistribution profiles were similar to those of 99m Tc-and 111 In-labeled C2Am (25) .
Discussion
Cell death, whether by apoptosis or necrosis, has attracted considerable attention as an imaging target since it is a generic marker for the presence of disease and additionally, in the case of cancer, a marker of response to treatment (4, 29) . A number of cell death imaging agents have been developed, with some interacting with intracellular targets, such as CC3 (30), cytosolic proteins (31, 32) and the mitochondrial membrane potential (33); or with extracellular targets, including exposed extracellular DNA (34), histones (35) and plasma membrane phospholipids (6, 36) . Plasma membrane phospholipids, such as PS and phosphatidylethanolamine (PE), which are normally present on the inner leaflet of the plasma membrane bilayer, are exposed on the surface of apoptotic cells and in necrotic cells by permeabilization of the plasma membrane to the imaging agent (37, 38) . These phospholipids are an attractive target since in necrotic cells their exposure is persistent, which makes timing of imaging after cell death less critical, and they are abundant and therefore potentially capable of giving high signal-to-noise when bound by the imaging probe (7, 39) . In a previous study, titration of isolated apoptotic cells with fluorescently labeled C2Am gave an exposed PS concentration of 100 -300 pmol/10 6 cells (5), which assuming a tumor cell density in vivo of ~10 8 cells/ml, corresponds to a PS concentration in apoptotic tumor tissue of 10 -30 μM. This concentration is considerably in excess of the estimated minimum MSOT-detectable dye concentration in mouse tissue of 0.5 -2 μM (14) .
We have shown previously that C2A, when conjugated to labels detectable by magnetic resonance (6, 9) , radionuclide and fluorescence imaging (25) , is capable of detecting tumor cell death in vivo by binding to exposed PS. We have also shown that C2Am is more specific than Annexin V in detecting cell death, which also binds PS, since C2Am shows less binding to viable cells (5) Several targeted contrast agents for optoacoustic imaging of tumors have been developed in recent years (14, 40, 41) , including dye-conjugated EGF, which was used to image EGF receptor expression in an orthotropic pancreatic cancer model (42) , and a dye-conjugated cyclic peptide, which was used to image expression of the integrin, α v β 3, in an orthotropic brain tumor model (43) . There has been a recent preliminary study in which a PS-binding antibody was used to image cell death in an implanted human breast cancer model in nude mice (44) . However, the injected concentration was not specified nor was the statistical significance of the increase in signal intensity, which only appeared to be increased significantly at a time when the tumor was already shrinking. Moreover, there was no histological validation, or control measurements with a non-PS binding IgG.
We have shown here that MSOT measurements with a NIR fluorophore-labeled PS binding protein, C2Am-750, can be used to create 3D images of tumor cell death in human colorectal xenografts treated with a novel TRAILR2 agonist, MEDI3039. The C2Am-750 signal in treated Colo205 tumors increased as early as 3 h post probe injection, and at 24 h the signal-to-background ratio, for those regions showing the greatest binding, was >10. There was negligible retention of a site-directed mutant of C2Am, which is inactive in PS binding (iC2Am-750) ( Figure 6 A-C). Positive MSOT signal showed a good correlation with staining of apoptotic cells in tumor sections.
A limitation of the current study was the very high levels of tumor cell death following treatment with MEDI3039. However, we have shown previously that fluorescence imaging with C2Am labeled with AlexaFluor™-750 C5-maleimide was capable of detecting 5-FU-induced cell death in Colo205 tumors, where CC3 staining in tumor sections increased from 1 -2% pre-treatment to 2 -5% post treatment (25) .
Moreover, we have shown here that MSOT imaging with C2Am labeled with another NIR fluorophore was also capable of detecting 5-FU-induced tumor cell death.
Tumor cell death in the clinic can range from less than 2% before treatment to 5%-15% after treatment (45) .
Optoacoustic imaging with the C2Am probe described here has the potential to be used in the clinic to assess early treatment response in relatively superficial tumors, such as in the breast (46) , and in an endoscopic format (47) , for assessing treatment response in tumors in the gastrointestinal tract. 
Figure legends
